** Shares of Eris Lifesciences ERIS.NS shed 4.3% to
1,196.45 rupees
** Drugmaker reports ~19% Y/Y drop in Q3 consol net profit,
profit margin contracts to 11.9% from 20.9% year ago
** Even though revenue grew ~50% Y/Y, it was offset due to
expenses tied to change in ERIS's business mix due to its
acquisition of Biocon's BION.NS branded formulations business,
ERIS says
** ERIS's total expenses jump ~64% Y/Y
** Avg rating of eight analysts on ERIS at "Buy"; median PT
is 1,505 rupees - LSEG data
** Stock gained ~51% in 2024
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))